Fairmont Banff Springs Floorplan

Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2015
Here are the related meetings in 2020:
Antibodies as Drugs: From B Cell Biology to New Treatments (B1)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Antibodies as Drugs: Immunological Scaffolds as Therapeutics (J8)
Organizer(s) Pablo Umaña, Mark X. Sliwkowski and Martin J. Glennie
February 8—13, 2015
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Oct 9, 2014
Abstract Deadline: Nov 12, 2014
Scholarship Deadline: Oct 9, 2014
Discounted Registration Deadline: Dec 9, 2014
Sponsored by Genentech, Inc., ImmunoGen, Inc., Mersana Therapeutics, OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Shire Human Genetic Therapies
Summary of Meeting:
Monoclonal antibodies are now an established class of drugs in oncology and inflammation. In addition, exciting progress has been recently made on next-generation, engineered therapeutic antibodies and alternative immunological scaffolds, with the first examples from this class being recently approved by the FDA and EMA. This Keystone Symposia meeting will review progress in this area, including lessons learned in the clinic and how this can be applied to new targets and drug candidates. The meeting will cover major areas of activity including: 1) Increasing antibody potency via antibody engineering, better engaging immune effector cells, and improvements in targeted delivery of effectors via fusion proteins and via conjugation of cytotoxic drugs; 2) Applying alternative targeting approaches to increase the therapeutic window, such as pre-targeting and site-specific antibody unmasking; 3) Novel antibodies in areas outside of oncology, including infectious diseases, neurology and chronic inflammation; 4) Engineering antibodies and scaffolds for alternative delivery routes and improved disposition; 5) Clinical progress with multi-specific antibodies; and 6) Recent advances in (i) addressing difficult targets such as GPCRs and ion channels, (ii) alternative immunological scaffolds, and (iii) novel antibody library technologies. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Tumor Immunology - Multidisciplinary Science Driving Combination Therapy,” which will be co-located with this meeting.
View Scholarships/Awards
Monoclonal antibodies are now an established class of drugs in oncology and inflammation. In addition, exciting progress has been recently made on next-generation, engineered therapeutic antibodies and alternative immunological scaffolds, with the first examples from this class being recently approved by the FDA and EMA. This Keystone Symposia meeting will review progress in this area, including lessons learned in the clinic and how this can be applied to new targets and drug candidates. The meeting will cover major areas of activity including: 1) Increasing antibody potency via antibody engineering, better engaging immune effector cells, and improvements in targeted delivery of effectors via fusion proteins and via conjugation of cytotoxic drugs; 2) Applying alternative targeting approaches to increase the therapeutic window, such as pre-targeting and site-specific antibody unmasking; 3) Novel antibodies in areas outside of oncology, including infectious diseases, neurology and chronic inflammation; 4) Engineering antibodies and scaffolds for alternative delivery routes and improved disposition; 5) Clinical progress with multi-specific antibodies; and 6) Recent advances in (i) addressing difficult targets such as GPCRs and ion channels, (ii) alternative immunological scaffolds, and (iii) novel antibody library technologies. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Tumor Immunology - Multidisciplinary Science Driving Combination Therapy,” which will be co-located with this meeting.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, FEBRUARY 8
MONDAY, FEBRUARY 9
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
TUESDAY, FEBRUARY 10
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
WEDNESDAY, FEBRUARY 11
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
THURSDAY, FEBRUARY 12
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
FRIDAY, FEBRUARY 13
Conference Program Print | View meeting in 24 hr (international) time
SUNDAY, FEBRUARY 8
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
8:00—9:00 AM
Keynote Address
Suzanne L. Topalian,
Johns Hopkins University School of Medicine, USA
Antibodies Blocking the PD-1 Pathway: A New Age for Cancer Therapy
Antibodies Blocking the PD-1 Pathway: A New Age for Cancer Therapy
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
8:00—9:30 AM
Keynote Session
Axel Hoos,
GlaxoSmithKline, USA
Combination Therapies – Immunology Meets Oncology
Combination Therapies – Immunology Meets Oncology
Robert D. Schreiber,
Washington University School of Medicine, USA
Using Genomics Approaches to Inform Cancer Immunotherapy
Using Genomics Approaches to Inform Cancer Immunotherapy
9:00—11:30 AM
Antibody Drug Conjugates in the Clinic
*
Peter D. Senter,
Seattle Genetics Inc., USA
Potent Antibody-Based Conjugates for Cancer Therapy: From Early-Stage Research to a Clinically Approved Drug
Potent Antibody-Based Conjugates for Cancer Therapy: From Early-Stage Research to a Clinically Approved Drug
William C. Olson,
Regeneron Pharmaceuticals, Inc., USA
Clinical-Stage ADCs: What's Trending Amongst this 50ish Crowd
Clinical-Stage ADCs: What's Trending Amongst this 50ish Crowd
Joseph J. Bellucci,
Duke University, USA
Short Talk: A Non-Canonical Function of Sortase Enables Conjugation of Small Molecules to Lysine Residues in Proteins
Short Talk: A Non-Canonical Function of Sortase Enables Conjugation of Small Molecules to Lysine Residues in Proteins
Philipp Müller,
University Hospital Basel, Switzerland
Short Talk: The Antibody-Drug-Conjugate T-DM1 Induces Potent Anti-Tumor Immunity in HER2+ Breast Cancer: Implications for Combinations with Immunotherapy
Short Talk: The Antibody-Drug-Conjugate T-DM1 Induces Potent Anti-Tumor Immunity in HER2+ Breast Cancer: Implications for Combinations with Immunotherapy
Sabine Imhof-Jung,
Roche Innovation Center Penzberg, Germany
Clinical Progress with Anti-Cancer Cytolytic Fusion Proteins
Clinical Progress with Anti-Cancer Cytolytic Fusion Proteins
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
9:30—11:45 AM
Inflammation and the Dynamics of the Tumor Microenvironment
Robert Peter Gale,
Hammersmith and Celgene, USA
The Diversity of Myeloid Cell Populations Driving Carcinogenesis
The Diversity of Myeloid Cell Populations Driving Carcinogenesis
Amy-Jo Casbon,
Amgen, USA
Short Talk: Tumors Reprogram Early Myeloid Differentiation in the Bone Marrow to Generate Immunosuppressive Neutrophils
Short Talk: Tumors Reprogram Early Myeloid Differentiation in the Bone Marrow to Generate Immunosuppressive Neutrophils
Guido Kroemer,
Cordeliers Research Center, France
How Chemotherapeutics Start an Intratumoral Anticancer Immune Response
How Chemotherapeutics Start an Intratumoral Anticancer Immune Response
*
Elizabeth M. Jaffee,
Johns Hopkins University, USA
Combinatorial Immunotherapies with the Potential to Reverse the Carcinogenesis Process
Combinatorial Immunotherapies with the Potential to Reverse the Carcinogenesis Process
Natasa Obermajer,
University of Pittsburgh, USA
Short Talk: Th17 into Treg Cell Conversion: A Novel Pathway of Treg Cell Emergence
Short Talk: Th17 into Treg Cell Conversion: A Novel Pathway of Treg Cell Emergence
2:30—4:30 PM
Workshop 1: Novel Scaffolds
*
Pablo Umaña,
Roche Innovation Center Zürich, Switzerland
*
Michael Stumpp,
Molecular Partners, Switzerland
David P. Chimento,
Rockland Immunochemicals, Inc., USA
Differential Affinity Single Domain Antibodies: Novel Agents for in vivo Imaging and Targeted Therapies
Differential Affinity Single Domain Antibodies: Novel Agents for in vivo Imaging and Targeted Therapies
Birgit Dreier,
University of Zürich, Switzerland
Generic Adenovirus Delivery System Using Bispecific DARPin-Based Adapters
Generic Adenovirus Delivery System Using Bispecific DARPin-Based Adapters
Kyle Landgraf,
AvidBiotics Corp., USA
Engineering Human MICA as a Novel Immunotherapeutic Scaffold
Engineering Human MICA as a Novel Immunotherapeutic Scaffold
Tao Dao,
Memorial Sloan Kettering, USA
Potent Therapeutic Activity of a TCR-Mimic Bi-Specific T Cell Engager Antibody against Human Cancers Expressing WT1 in the Context of HLA-A02
Potent Therapeutic Activity of a TCR-Mimic Bi-Specific T Cell Engager Antibody against Human Cancers Expressing WT1 in the Context of HLA-A02
Johan Nilvebrant,
Royal Institute of Technology, Sweden
ADAPT - A Novel Scaffold Protein for Radionuclide Molecular Imaging
ADAPT - A Novel Scaffold Protein for Radionuclide Molecular Imaging
Sabrina Oliveira,
Utrecht University, Netherlands
Nanobody-Photosensitizer Conjugates as an Alternative Format for Targeted Photodynamic Therapy
Nanobody-Photosensitizer Conjugates as an Alternative Format for Targeted Photodynamic Therapy
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
2:30—4:30 PM
Workshop 1: Integration of Science through Collaboration - New Models
*
Axel Hoos,
GlaxoSmithKline, USA
*
Ira Mellman,
Genentech, Inc., USA
*
Padmanee Sharma,
University of Texas MD Anderson Cancer Center, USA
*
Elizabeth M. Jaffee,
Johns Hopkins University, USA
Arthur Machlenkin,
Pantheon Biosciences Ltd, Israel
Identification of Novel Immuno-Modulatory Targets for Cancer Immunotherapy
Identification of Novel Immuno-Modulatory Targets for Cancer Immunotherapy
Bruce Freimark,
Pulse Biosciences, USA
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid-Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid-Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment
Marit Martha van Buuren,
Neon Therapeutics, USA
Intratumoral CD4+ T Cell Reactivity Against Mutated Antigens Is Commonly Observed in Human Melanoma
Intratumoral CD4+ T Cell Reactivity Against Mutated Antigens Is Commonly Observed in Human Melanoma
Francisca Wollerton,
F-star, UK
Modular Antibody TechnologyTM Platform Delivers Molecules of Diverse Formats and Biology
Modular Antibody TechnologyTM Platform Delivers Molecules of Diverse Formats and Biology
Jennie R. Lill,
Genentech, Inc., USA
Mass-Spectrometry Based Characterization of the MHC-I Peptide Repertoire in Response to Drug Treatment
Mass-Spectrometry Based Characterization of the MHC-I Peptide Repertoire in Response to Drug Treatment
5:00—7:00 PM
Antibody-Targeted Fusion Proteins for Cancer Therapy
Mark X. Sliwkowski,
Genentech, Inc., USA
Antibody Therapeutics in the Treatment of HER2-Positive Cancer: Past, Present and Future
Antibody Therapeutics in the Treatment of HER2-Positive Cancer: Past, Present and Future
Sherie L. Morrison,
University of California, Los Angeles, USA
Antibody Fusions with Interferon for the Treatment of Malignancy
Antibody Fusions with Interferon for the Treatment of Malignancy
*
Tibor P. Keler,
Celldex Therapeutics, Inc., USA
DC-Targeted Antibody Fusions as Cancer Vaccines
DC-Targeted Antibody Fusions as Cancer Vaccines
Christian Klein,
Roche, Switzerland
Short Talk: CEA-Targeted IL-2 Variant (IL2v)-Based Immunocytokine for Immunotherapy of Cancer
Short Talk: CEA-Targeted IL-2 Variant (IL2v)-Based Immunocytokine for Immunotherapy of Cancer
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
5:00—7:15 PM
Genetics and Epigenetics of the Immune System
Tak W. Mak,
Campbell Family Institute for Breast Cancer, Canada
Genetic and Epigenetic Alterations that Drive Neoantigen Development
Genetic and Epigenetic Alterations that Drive Neoantigen Development
Morten Frier Gjerstorff,
University of Southern Denmark, Denmark
Short Talk: Oncogenic Functions of Cancer/Testis Antigen SSX2 Highlight its Therapeutic Potential
Short Talk: Oncogenic Functions of Cancer/Testis Antigen SSX2 Highlight its Therapeutic Potential
*
Laurence Zitvogel,
Institut Gustave Roussy, France
Gut Microbiota and Anticancer Immune Responses
Gut Microbiota and Anticancer Immune Responses
Eduardo M. Sotomayor,
Moffitt Cancer Center and Research Institute, USA
Combinatorial Approaches that Integrate Epigenetic Therapy with Immunotherapy
Combinatorial Approaches that Integrate Epigenetic Therapy with Immunotherapy
Brian H. Ladle,
Johns Hopkins University, USA
Short Talk: De novo DNA Methylation by DNMT3a Controls CD8+ T Cell Fate Decisions following Activation
Short Talk: De novo DNA Methylation by DNMT3a Controls CD8+ T Cell Fate Decisions following Activation
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:15 AM
Antibodies for Cancer Immunotherapy
Alan J. Korman,
Bristol-Myers Squibb, USA
Anti-Tumor Activity of Immunomodulatory Antibodies
Anti-Tumor Activity of Immunomodulatory Antibodies
*
Martin J. Glennie,
University of Southampton, UK
Agonistic Antibodies Targeting Costimulatory Receptors
Agonistic Antibodies Targeting Costimulatory Receptors
*
Pablo Umaña,
Roche Innovation Center Zürich, Switzerland
Enhancing Immune Effector Functions: Gazyva and Beyond
Enhancing Immune Effector Functions: Gazyva and Beyond
Patrick A. Baeuerle,
Amgen Research (Munich) GmbH, Germany
Clinical Progress with T Cell-Engaging Bispecific Antibodies
Clinical Progress with T Cell-Engaging Bispecific Antibodies
Elizabeth E. Evans,
Vaccinex, Inc., USA
Short Talk: Anti-Semaphorin 4D Therapeutic Antibody Recruits Activated Tumor Infiltrating Leukocytes and Reverses Tumor Growth
Short Talk: Anti-Semaphorin 4D Therapeutic Antibody Recruits Activated Tumor Infiltrating Leukocytes and Reverses Tumor Growth
Rupali Das,
Children's Hospital of Philadelphia, USA
Short Talk: Cancer Immunotherapeutic Potential of NKTT320, a Novel Human iNKT Cell Activating Monoclonal Antibody
Short Talk: Cancer Immunotherapeutic Potential of NKTT320, a Novel Human iNKT Cell Activating Monoclonal Antibody
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
8:00—11:00 AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immunotherapy
*
Ton N. Schumacher,
Netherlands Cancer Institute, Netherlands
Neo-Antigens in Human Cancer
Neo-Antigens in Human Cancer
Lélia Delamarre,
Genentech, Inc., USA
Short Talk: Predictive Identification of Immunogenic Mutations in Cancer
Short Talk: Predictive Identification of Immunogenic Mutations in Cancer
Matthew M. Gubin,
Washington University in St. Louis, USA
Short Talk: Checkpoint Blockade Cancer Therapy Targets Tumor-Specific Mutant Antigens
Short Talk: Checkpoint Blockade Cancer Therapy Targets Tumor-Specific Mutant Antigens
Jonathan D. Powell,
Johns Hopkins University School of Medicine, USA
Targeting mTOR and Metabolism to Enhance Anti-Tumor Immunotherapy
Targeting mTOR and Metabolism to Enhance Anti-Tumor Immunotherapy
Antony Rosen,
Johns Hopkins University School of Medicine, USA
Cancer and the Autoimmune Rheumatic Diseases: Mechanistic Insights
Cancer and the Autoimmune Rheumatic Diseases: Mechanistic Insights
5:00—7:00 PM
Alternative Tumor Targeting Approaches
*
Karl Dane Wittrup,
Massachusetts Institute of Technology, USA
Limits of Tumor Targeting in Immunotherapy: Theory and Experiment
Limits of Tumor Targeting in Immunotherapy: Theory and Experiment
Bryan A. Irving,
CytomX Therapeutics, Inc, USA
Probodies Empower a New Generation of Antibody Immunotherapies
Probodies Empower a New Generation of Antibody Immunotherapies
Peter Molloy,
Immunocore Ltd., UK
ImmTACs: Bi-specific TCR-based Reagents for Targeted Cancer Immunotherapy
ImmTACs: Bi-specific TCR-based Reagents for Targeted Cancer Immunotherapy
Heather A. Huet,
Novartis Institutes for Biomedical Research, USA
Short Talk: Targeting Ovarian Cancer with ESK1, a Glycoengineered TCR-Mimic Antibody Directed Against the Intracellular Transcription Factor WT1 with Enhanced ADCC Killing
Short Talk: Targeting Ovarian Cancer with ESK1, a Glycoengineered TCR-Mimic Antibody Directed Against the Intracellular Transcription Factor WT1 with Enhanced ADCC Killing
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
5:00—7:00 PM
Human Immunology: Functional Insights for Cancer Immunotherapy
Eliane Piaggio,
Immunity and Cancer - Institut Curie / INSERM, France
Short Talk: Lymph Node Invasion by Tumor Cells Modifies the Distribution and Phenotype of Dendritic and T Cell Subsets in Breast Cancer Patients
Short Talk: Lymph Node Invasion by Tumor Cells Modifies the Distribution and Phenotype of Dendritic and T Cell Subsets in Breast Cancer Patients
*
Pia Kvistborg,
Netherlands Cancer Institute, Netherlands
Effects of Checkpoint Targeting on the Tumor-Specific T Cell Response
Effects of Checkpoint Targeting on the Tumor-Specific T Cell Response
Steven M. Larson,
Memorial Sloan-Kettering Cancer Center, USA
Radioimmunotherapy (RIT) of Solid Tumors
Radioimmunotherapy (RIT) of Solid Tumors
Jay A. Berzofsky,
NCI, National Institutes of Health, USA
Talk Title to be Announced
Talk Title to be Announced
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:15 AM
Clinical Progress with Bispecific Antibodies for Dual Blockade
*
Mark X. Sliwkowski,
Genentech, Inc., USA
Gabriele Schaefer,
Genentech, Inc., USA
MEHD7495A, a Dual-Action-Antibody Targeting HER3 and EGFR: Preclinical and Clinical Evaluation
MEHD7495A, a Dual-Action-Antibody Targeting HER3 and EGFR: Preclinical and Clinical Evaluation
Alexey Lugovskoy,
Merrimack Pharmaceuticals Inc., USA
MM-141: Dual Antibody Inhibitor of IGF-1R and ErbB3 Targeting Redundancies and Adaptation in Oncogenic Signaling
MM-141: Dual Antibody Inhibitor of IGF-1R and ErbB3 Targeting Redundancies and Adaptation in Oncogenic Signaling
Oliver Krieter,
, Germany
Clinical Progress with RG7221 (RO5520985), a Bi-Specific Human IgG1 Antibody Against Ang-2 and VEGF-A for the Treatment of Cancer
Clinical Progress with RG7221 (RO5520985), a Bi-Specific Human IgG1 Antibody Against Ang-2 and VEGF-A for the Treatment of Cancer
Tariq Ghayur,
AbbVie Inc., USA
Preclinical and Clinical Progress of Dual-Variable-Domain-Ig (DVD-IgTM) Molecules for Autoimmune Indications
Preclinical and Clinical Progress of Dual-Variable-Domain-Ig (DVD-IgTM) Molecules for Autoimmune Indications
Mathias Locher,
Covagen AG, Switzerland
Short Talk: COVA322: A Clinical Stage TNF/IL-17A Bispecific FynomAb for the Treatment of Inflammatory Diseases
Short Talk: COVA322: A Clinical Stage TNF/IL-17A Bispecific FynomAb for the Treatment of Inflammatory Diseases
Miho Funaki,
Chugai Pharmaceutical Co. Ltd., Japan
Short Talk: Novel Bispecific Antibody against Activated Factor IXa and Factor X (ACE910) for Treatment of Hemophilia A
Short Talk: Novel Bispecific Antibody against Activated Factor IXa and Factor X (ACE910) for Treatment of Hemophilia A
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
8:00—11:00 AM
Influence of Conventional Therapies on the Immune System
Padmanee Sharma,
University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies
From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies
*
Ira Mellman,
Genentech, Inc., USA
Targeted Molecular Therapy Takes on Immunotherapy
Targeted Molecular Therapy Takes on Immunotherapy
Dan G. Duda,
Harvard Medical School, Massachusetts General Hospital, USA
Short Talk: Rationally Combining Antiangiogenic Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma
Short Talk: Rationally Combining Antiangiogenic Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma
Daniel E. Speiser,
Ludwig Center, University of Lausanne, Switzerland
Multidisciplinary Approaches to Target both Cancer Cell-Internal and -External Disease Mechanisms
Multidisciplinary Approaches to Target both Cancer Cell-Internal and -External Disease Mechanisms
Roopa Srinivasan,
GlaxoSmithKline, USA
Effects of Targeted Therapies on Tumor and Immune System
Effects of Targeted Therapies on Tumor and Immune System
5:00—7:00 PM
Antibodies for Infectious Diseases
*
Antonio Lanzavecchia,
Institute for Research in Biomedicine, Switzerland
Broadly Neutralizing Anti-Viral Antibodies
Broadly Neutralizing Anti-Viral Antibodies
Yaoxing Huang,
Aaron Diamond AIDS Research Center, USA
Passive Immunization Approaches to HIV Prevention
Passive Immunization Approaches to HIV Prevention
Ian Huh,
California State University, Fresno, USA
Short Talk: Neutralization of Listeria monocytogenes by Single Domain Antibodies
Short Talk: Neutralization of Listeria monocytogenes by Single Domain Antibodies
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
5:00—7:15 PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therapies and Immune Modulators
Laurence J. N. Cooper,
ZIOPHARM Oncology, Inc., USA
Genetic Modification of T Cells Using Sleeping Beauty System for Human Applications
Genetic Modification of T Cells Using Sleeping Beauty System for Human Applications
*
Cornelis J. M. Melief,
Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Synergy of Therapeutic Vaccination Against HPV16 Oncogenic Proteins and Conventional Chemotherapeutics
Synergy of Therapeutic Vaccination Against HPV16 Oncogenic Proteins and Conventional Chemotherapeutics
Khaled H. Barakat,
University of Alberta, Canada
Short Talk: Rational Design of Small Molecule Immune Checkpoints' Inhibitors
Short Talk: Rational Design of Small Molecule Immune Checkpoints' Inhibitors
Jolanda de Vries,
NCMLS, Radboud University Medical Center, Netherlands
Natural Dendritic Cell Vaccine: A More Powerful Next Generation?
Natural Dendritic Cell Vaccine: A More Powerful Next Generation?
Sandeep T. Koshy,
Harvard University, USA
Short Talk: Tumor Immunomodulation Using an Injectable Biomaterials Scaffold
Short Talk: Tumor Immunomodulation Using an Injectable Biomaterials Scaffold
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:15 AM
Engineering Immunological Scaffolds for Improved Delivery and Disposition
*
Serge Muyldermans,
Vrije Universiteit Brussel, Belgium
Nanobodies for Alternative Delivery Routes
Nanobodies for Alternative Delivery Routes
Kristen M. Picha,
Centyrex, Janssen Research & Development, USA
Novel Delivery Strategies for Alternative Scaffolds
Novel Delivery Strategies for Alternative Scaffolds
Tomoyuki Igawa,
Chugai Pharmabody Research, Singapore
Engineered pH-Dependent Binding Antibody for Efficient Elimination of Soluble Antigen from Plasma
Engineered pH-Dependent Binding Antibody for Efficient Elimination of Soluble Antigen from Plasma
Yu-Ju Gloria Meng,
Genentech, Inc., USA
Short Talk: Intravitreally Injected Bispecific F(ab’)2 Had Similar Intraocular Concentrations and Reduced Circulating Concentrations Compared to IgG
Short Talk: Intravitreally Injected Bispecific F(ab’)2 Had Similar Intraocular Concentrations and Reduced Circulating Concentrations Compared to IgG
Jens Niewoehner,
Roche Pharma Research and Early Development, Germany
Short Talk: Engineering a Brain Shuttle for Therapeutic Protein Delivery
Short Talk: Engineering a Brain Shuttle for Therapeutic Protein Delivery
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
8:00—11:00 AM
Methodological Advances in Clinical and Biomarker Investigation
James P. Allison,
University of Texas MD Anderson Cancer Center, USA
Investigating Emerging Checkpoint Targets and their Modulators
Investigating Emerging Checkpoint Targets and their Modulators
Taha Merghoub,
Memorial Sloan-Kettering Cancer Center, USA
Genetic Basis Underlying Clinical Response to Checkpoint Blockade
Genetic Basis Underlying Clinical Response to Checkpoint Blockade
2:30—4:30 PM
Workshop 2: New Library Design and Screening Technologies
*
Pablo Umaña,
Roche Innovation Center Zürich, Switzerland
*
Catherine Hutchings,
Heptares Therapeutics, UK
Belay Gessesse Bezabeh,
University of Tokyo, Japan
Cell-Free Synthesis of the Human Chemokine G-Protein Coupled Receptor for Future Antibody Screening
Cell-Free Synthesis of the Human Chemokine G-Protein Coupled Receptor for Future Antibody Screening
Ling Chen,
Guangzhou Institute of Biomedicine and Health, CAS, China
Rapid Generation of Antiviral Antibodies for Human Application in Rhesus macaques in Responding to Emerging Influenza and Virulent Viral Infections
Rapid Generation of Antiviral Antibodies for Human Application in Rhesus macaques in Responding to Emerging Influenza and Virulent Viral Infections
Amandeep K. Gakhal,
Sutro Biopharma, USA
Discovery and Characterization of Therapeutic Antibodies for an Engineered Cell-Free Expression System
Discovery and Characterization of Therapeutic Antibodies for an Engineered Cell-Free Expression System
Ben Hoffstrom,
Fred Hutchinson Cancer Research Center, USA
High-Throughput Screening for Monoclonal Antibodies to Multiplexed Antigens
High-Throughput Screening for Monoclonal Antibodies to Multiplexed Antigens
Michael-Paul Robinson,
Cornell University, USA
Production of Full-length Antibodies in the Cytoplasm of E. coli
Production of Full-length Antibodies in the Cytoplasm of E. coli
Imre Kacskovics,
ImmunoGenes Ltd, Hungary
Transgenic Animals that Overexpress the Neonatal Fc Receptor (FcRn) Have Improved Antibody Generation
Transgenic Animals that Overexpress the Neonatal Fc Receptor (FcRn) Have Improved Antibody Generation
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
2:30—4:30 PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunotherapy - Lessons from Failures to Enable Future Successes
*
Cornelis J. M. Melief,
Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
*
James P. Allison,
University of Texas MD Anderson Cancer Center, USA
Jason R. Baird,
Earle A. Chiles Research Institute, USA
Radiation Therapy Combined with Novel Oligonucleotides Targeting STING in Tumor Stroma Result in Cure of Established Tumors
Radiation Therapy Combined with Novel Oligonucleotides Targeting STING in Tumor Stroma Result in Cure of Established Tumors
Hélène Salmon,
Icahn School of Medicine at Mount Sinai, USA
In situ Activation and Expansion of CD103+ DCs at the Tumor Site Dramatically Increase Melanoma Response to BRAF and PDL1 Inhibition Therapy
In situ Activation and Expansion of CD103+ DCs at the Tumor Site Dramatically Increase Melanoma Response to BRAF and PDL1 Inhibition Therapy
Katherine E. Lewis,
Bristol-Myers Squibb Company, USA
Dual Targeting of PD-1 and LAG-3 Demonstrates Superior Efficacy to Blocking Either PD-1 or LAG-3 Alone in Pre-Clinical Solid and Hematological Tumor Models
Dual Targeting of PD-1 and LAG-3 Demonstrates Superior Efficacy to Blocking Either PD-1 or LAG-3 Alone in Pre-Clinical Solid and Hematological Tumor Models
Carola H. Ries,
Roche Innovation Center Munich, Germany
Targeting Tumor-Associated Macrophages with Anti-CSF1R Antibody in Combination with Chemotherapy
Targeting Tumor-Associated Macrophages with Anti-CSF1R Antibody in Combination with Chemotherapy
Ryan Rountree,
Nurix, Inc., USA
Poxvirus-Based Active Immunotherapy Induces PD-L1 Expression in the Tumor Microenvironment and Results in Dramatic Anti-Tumor Efficacy in Combination with PD-1 Axis Blockade
Poxvirus-Based Active Immunotherapy Induces PD-L1 Expression in the Tumor Microenvironment and Results in Dramatic Anti-Tumor Efficacy in Combination with PD-1 Axis Blockade
Peter R. Rhode,
Altor BioScience Corp., USA
Enhanced Efficacy of Immune Checkpoint Blockers and Therapeutic Antibodies in Combination with an IL-15-Based Superagonist Complex in Various Mouse Tumor Models
Enhanced Efficacy of Immune Checkpoint Blockers and Therapeutic Antibodies in Combination with an IL-15-Based Superagonist Complex in Various Mouse Tumor Models
5:00—6:45 PM
Addressing Difficult Targets - GPCRs and Ion Channels
*
Catherine Hutchings,
Heptares Therapeutics, UK
Using Stabilized Receptors as Antigens to Generate Therapeutic Antibodies to GPCR Targets
Using Stabilized Receptors as Antigens to Generate Therapeutic Antibodies to GPCR Targets
Vaughn V. Smider,
The Scripps Research Institute, USA
Ultralong CDR3s for Targeting Ion Channels and GPCRs
Ultralong CDR3s for Targeting Ion Channels and GPCRs
Caroline Colley,
MedImmune, UK
Identifying Antibodies to GPCRs and Ion-Channels
Identifying Antibodies to GPCRs and Ion-Channels
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
5:00—6:45 PM
Scientific and Clinical Progress in Combination Therapy
*
Axel Hoos,
GlaxoSmithKline, USA
F. Stephen Hodi,
Dana-Farber Cancer Institute, USA
Immunological Scaffolds as Therapeutics: A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients
Immunological Scaffolds as Therapeutics: A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients
Cassian Yee,
University of Texas MD Anderson Cancer Center, USA
Adoptive T Cell Therapy: A Personalized Approach for Common Cancers
Adoptive T Cell Therapy: A Personalized Approach for Common Cancers
Silvia C. Formenti,
New York University Langone Medical Center, USA
Combination Therapy Potential of Radiation Therapy as in-situ Vaccination
Combination Therapy Potential of Radiation Therapy as in-situ Vaccination
Following Session is for Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)
7:15—8:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |